Quick Answer
Akebia Therapeutics, Inc. reported Long-Term Debt of $48.25 million for fiscal year 2025.
Akebia Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $48.25M | +24.7% |
| 2024 | $38.69M | +125.2% |
| 2023 | $17.18M | -49.6% |
| 2022 | $34.08M | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $96.38M | +27.1% |
| 2019 | $75.81M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $47.64M | +24.2% | +1.2% |
| June 30, 2025 | $47.06M | +23.7% | +1.2% |
| March 31, 2025 | $46.51M | +54.3% | +20.2% |
| December 31, 2024 | $38.69M | +125.2% | +0.9% |
| September 30, 2024 | $38.35M | +10.8% | +0.9% |
| June 30, 2024 | $38.03M | +105.7% | +26.2% |
| March 31, 2024 | $30.14M | +14.6% | +75.4% |
| December 31, 2023 | $17.18M | -49.6% | -50.4% |
- Akebia Therapeutics, Inc. showed an increase of +24.7% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2025 period, Akebia Therapeutics, Inc.’s long-term debt has declined by 36.3% (from $75.81 million to $48.25 million).
- The most recent figure is from Akebia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: